Crossref

1. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy

- Gamal Eldeen Esmat

- Wafa Al Akel

- Rasha Ahmed Abdel Aziz

- Ahmed Al Sayed Taha

- Dina Sabry

- Laila A. Rashed

- Aya Mostafa

- Amany Y. El Kazaz

- Sahar H. Ahmed

2. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt

- Ahmed Nagaty

- Ekram W. Abd El-Wahab

- Tatsuo Kanda

3. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens

- Maissa El-Raziky

- Marwa Khairy

- Ahmed Fouad

- Ahmed Salama

- Aisha Elsharkawy

- Omnia Tantawy

4. Serum MicroRNAs as predictors for fibrosis progression and response to direct‐acting antivirals treatment in hepatitis C virus genotype‐4 Egyptian patients

- Rasha M. M. Khairy

- Safaa Said Hmmad

- Mohamed Sayed

- Hazem A. Ahmed

- Mona Abdel Monem Esmail

5. Hepatitis C genotype 4: The past, present, and future

- Tawhida Y Abdel-Ghaffar

6. ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides

- Patrick Brendan Timmons

- Chandralal M Hewage

7. The effect of the degree of hepatitis C-related fibrosis on the responsiveness to pegylated interferon α-2a versus pegylated interferon α-2b

- Yehia M. El Shazly

- Mohamed Abdel Hamid El Bokl

- Mohamed Abdel Moghny Mostafa

- Nanees A. Adel

- Mohamed O. Khalifa

- Ossama A. Ahmed

- Ahmed I. El Shafie

- Mohamed H.A. Fouad

- Gina G. Naguib

8. The current and future disease burden of chronic hepatitis C virus infection in Egypt

- Imam Waked

- Waheed Doss

- Manal Hamdy El-Sayed

- Chris Estes

- Homie Razavi

- Gamal Shiha

- Ayman Yosry

- Gamal Esmat

9. Pathology Predictors of Response to Combined Therapy of Chronic HCV Patients; Is it Applicable in the DAA Era?

- Samar Kamal Darweesh

10. Effect of sofosbuvir and ribavirin therapy on hearing

- Naema Ismail

- Gamal El-Serafy

- Amal Ewida

- Iman Eladawy

- Mona Abd-Elmo′men

11. The Efficacy of aHansenula-Derived 20 kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C

- Hany Shehab

- Tamer Elbaz

- Dalia Deraz

- Amal Hafez

- Inas Elattar

12. Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt’s hepatocellular cancer epidemic: simulation of alternatives

- Wenkang Ma

- Amr S Soliman

- Wagida A Anwar

- Ahmed Hablas

- Tamer B El Din

- Mohamed Ramadan

- Ibrahim A Seifeldin

- Mark L Wilson

13. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

- G. Schnell

- R. Tripathi

- J. Beyer

- T. Reisch

- P. Krishnan

- T. Dekhtyar

- M. Irvin

- C. Hall

- Y. Yu

- N. Mobashery

- R. Redman

- T. Pilot‐Matias

- C. Collins

14. Meta-analysis

- Brittany E. Yee

- Nghia H. Nguyen

- Bing Zhang

- Philip Vutien

- Carrie R. Wong

- Glen A. Lutchman

- Mindie H. Nguyen

15. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations

- Dalia Omran

- Mohamed Alboraie

- Rania A Zayed

- Mohamed-Naguib Wifi

- Mervat Naguib

- Mohamed Eltabbakh

- Mohamed Abdellah

- Ahmed Fouad Sherief

- Sahar Maklad

- Heba Hamdy Eldemellawy

- Omar Khalid Saad

- Doaa Mohamed Khamiss

- Mohamed El Kassas

16. Factors Affecting the Virological Response Among Chronic Hepatitis C Virus Patients in Yemen

- Zaid Mutahar Mohammed Alezzi

- Ayman Yosry Abd El Rehim

- Waleed Fouad Fathallah

- Mansour Ali Alamrani

- Fouad Hezam Othman

17. Antiviral peptides as promising therapeutic drugs

- Liana Costa Pereira Vilas Boas

- Marcelo Lattarulo Campos

- Rhayfa Lorrayne Araujo Berlanda

- Natan de Carvalho Neves

- Octávio Luiz Franco

18.

19. Antiviral peptidlerin SARS COV-2 ana proteaz yapısına bağlanma etkinliklerinin protein-yanaştırma yöntemi ile incelenmesi: In silico bir çalışma

- İlter DEMİRHAN

- Erkan ÖNER

- Ergul BELGE KURUTAS

20. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center

- Mohamed El Kassas

- Mohamed Eltabbakh

- Mohamed Elbadry

- Ahmed Tawheed

- Tamer Elbaz

21. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt

- Gamal Esmat

- Tamer Elbaz

- Aisha Elsharkawy

- Mohamed Abdullah

- Mohamed El Kassas

22. HCV in Egypt, prevention, treatment and key barriers to elimination

- Mohamed El Kassas

- Tamer Elbaz

- Aisha Elsharkawy

- Heba Omar

- Gamal Esmat

23. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care

- W. El‐Akel

- M. H. El‐Sayed

- M. El Kassas

- M. El‐Serafy

- M. Khairy

- K. Elsaeed

- K. Kabil

- M. Hassany

- A. Shawky

- A. Yosry

- M. K. Shaker

- Y. ElShazly

- I. Waked

- G. Esmat

- W. Doss

24. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

- Radwa Samir Hagag

- Morkoss Medhat Fakhry

- Ossama Ashraf Ahmed

- Shaimaa Abdalaleem Abdalgeleel

- Mahasen Aly Radwan

- Gina Gamal Naguib

25. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

- Goran Hauser

- Tahany Awad

- Kristian Thorlund

- Davor Štimac

- Mahasen Mabrouk

- Christian Gluud

26. Optimal Management of HCV Genotype 4

- Wael Abdel-Razek

- Imam Waked

27. Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues

- Gamal Esmat

- Mohamed El Kassas

- Mohamed Hassany

- Mohamed Gamil

- Maissa El Raziky

28. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis

- Brittany E Yee

- Nghia H Nguyen

- Bing Zhang

- Derek Lin

- Philip Vutien

- Carrie R Wong

- Glen A Lutchman

- Mindie H Nguyen

29. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

- Mahdiyar Pouresmaeeli

- Seyed Moayed Alavian

- Maryam Keshvari

- Shima Salimi

- Leila Mehrnoush

30. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals

- Nehal K. Abdel Fattah

- Sara M. Shaheen

- Osama A. Ahmed

- Kadry Elsaeed

- Nagwa A. Sabri

31. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting

- Gina Gamal Naguib

- Tari George Michael

- Yehia Elshazly

- Maha Magdy Wahdan

- Aya Mostafa

- Ossama Ashraf Ahmed

- Hany Dabbous

- Heba Ismail Saad Aly

- Mohamed Kamal Shaker

- Hosam Samir Elbaz

- Magdy El-Serafy

- Wahid Doss

- Sherief Abd-Elsalam

- Manal Hamdy El-Sayed

32. Management of hepatitis C genotype 4 in the directly acting antivirals era

- Emma Hathorn

- Ahmed M Elsharkawy

33. A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir

- A. Hanno

- D. Elwazzan

- M. Ibrahim

- R. Hafez

34. Genotype 4 hepatitis C virus-a review of a diverse genotype

- Michał Brzdęk

- Krystyna Dobrowolska

- Robert Flisiak

- Dorota Zarębska-Michaluk

35. Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir

- Islam Shah

- Nayab Munib

- Aliena Badshah

- Wazir Mohammad